PDF herunterladen
Thromb Haemost
DOI: 10.1055/a-2632-3100
Cellular Haemostasis and Platelets

Distinct Platelet Phenotype and Reactivity in Individuals with Permanent Atrial Fibrillation Treated with Direct Oral Anticoagulants: A Pilot Study

Marzia Miglionico   *
1   Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy
,
Francesca Maiorca   *
2   Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy
,
Annamaria Sabetta
2   Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy
,
Ludovica Lombardi
2   Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy
,
Tania D'amico
1   Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy
,
Alessandro Cincione
2   Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy
,
Giovanni Buoninfante
2   Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy
,
Marin Pecani
1   Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy
,
Marco Proietti
3   Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy
4   Division of Subacute Care, IRCCS Istituti Clinici Scientifici Maugeri, Milan, Italy
,
Giulio Francesco Romiti 
2   Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy
5   Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart and Chest Hospital, Liverpool, United Kingdom
,
Roberto Cangemi
2   Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy
,
Stefania Basili
2   Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy
,
Valeria Raparelli
2   Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy
,
Lucia Stefanini
2   Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy
6   Istituto Pasteur Italia - Fondazione Cenci-Bolognetti, Rome, Italy
› Institutsangaben
Funding The study was supported by Sapienza University Research Project 2023 (code: RG123188B4CD04C9) to L.S. and co-financed by the Next Generation EU (DM 1557 11.10.2022), in the context of the National Recovery and Resilience Plan, Investment PE8—Project Age-It: “Ageing Well in an Ageing Society.” The views and opinions expressed are only those of the authors and do not necessarily reflect those of the European Union or the European Commission. Neither the European Union nor the European Commission can be held responsible for them. G.F.R. is supported by a grant issued by Sapienza University of Rome (AR22419077BB6154).
› Weitere Informationen
   Lizenzen und Reprints


Abstract

Background

Atrial fibrillation (AF) is linked to an elevated risk of thromboembolic events. Despite the use of guideline-recommended direct anticoagulants (DOACs), a significant proportion of AF patients show a residual risk of thromboembolic events, driven by mechanisms that are not fully understood.

Objective

We conducted a pilot study to characterize the platelet function in DOACs-treated AF patients, to explore whether an association between platelets and the residual thromboembolic risk exists.

Methods

Within the Age-It project of the National Recovery and Resilience Plan, we examined by flow cytometry the platelet phenotype, reactivity, and mitochondrial function and quantified 12 inflammatory cytokines of individuals with DOACs-treated permanent AF without a history of stroke (n = 18, 66 ± 13 years, 39% females), compared with an age-, sex-, and comorbidity-matched control group without AF (n = 18, 65 ± 11 years, 39% females).

Results

Unstimulated circulating platelets of DOACs-treated AF displayed a low-adhesive phenotype compared with matched controls. Upon stimulation, platelets of DOACs-treated AF were hyporeactive to ADP and PAR1 stimulation, but hyper-reactive to GPVI stimulation (adjusted p < 0.01). The lower responsiveness to ADP correlated with increased plasmatic concentrations of IFN-γ (r = − 0.539; p < 0.05) and TNF-α (r = − 0.472; p < 0.05). The higher reactivity to GPVI associated with an increased mitochondrial function, which positively correlated with TNF-α levels.

Conclusion

Individuals with AF treated with DOACs exhibit low-grade inflammation and an altered platelet reactivity, suggesting a potential mechanism behind their residual thromboembolic risk. Further well-powered studies are warranted to test whether the observed platelet phenotype is implicated with the residual thromboembolic events in DOACs-treated AF patients.

Keywords

platelet physiology - cardiology - coagulation inhibitors - platelet glycoproteins

Data Availability Statement

The data supporting the findings of this study are available upon request from the corresponding author.


Authors' Contribution

M.M. enrolled patients, analyzed and interpreted the data, and contributed to the final manuscript; F.M. performed experiments, analyzed and interpreted the data, and contributed to the final manuscript; A.S. and L.L. performed the experiments and analyzed the data; T.D., A.C, G.B., and M.P. enrolled the study participants, collected clinical data, and stratified the patients; M.P., G.F.R., R.C., S.B, and V.R. designed the study, recruited the patients, and critically revised the manuscript; L.S. coordinated the study, analyzed and interpreted the data, and wrote the manuscript.


* These authors contributed equally to this study.


Supplementary Material



Publikationsverlauf

Eingereicht: 27. Dezember 2024

Angenommen: 10. Juni 2025

Accepted Manuscript online:
11. Juni 2025

Artikel online veröffentlicht:
24. Juni 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 

  • References

  • 1 Elliott AD, Middeldorp ME, Van Gelder IC, Albert CM, Sanders P. Epidemiology and modifiable risk factors for atrial fibrillation. Nat Rev Cardiol 2023; 20 (06) 404-417
    CrossrefPubMedSuche in Google Scholar
  • 2 Kamel H, Okin PM, Elkind MSV, Iadecola C. Atrial fibrillation and mechanisms of stroke: time for a new model. Stroke 2016; 47 (03) 895-900
    CrossrefPubMedSuche in Google Scholar
  • 3 Van Gelder IC, Rienstra M, Bunting KV. et al; ESC Scientific Document Group. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2024; 45 (36) 3314-3414
    CrossrefPubMedSuche in Google Scholar
  • 4 Johnson LS, Benz AP, Shoamanesh A. et al. Residual stroke risk among patients with atrial fibrillation prescribed oral anticoagulants: a patient-level meta-analysis from COMBINE AF. J Am Heart Assoc 2024; 13 (17) e034758
    PubMedSuche in Google Scholar
  • 5 Ding WY. Residual stroke risk in atrial fibrillation. Arrhythm Electrophysiol Rev 2021; 10 (03) 147-153
    PubMedSuche in Google Scholar
  • 6 Corica B, Lobban T, True Hills M, Proietti M, Romiti GF. Sex as a risk factor for atrial fibrillation-related stroke. Thromb Haemost 2024; 124 (04) 281-285
    Thieme ConnectPubMedSuche in Google Scholar
  • 7 Paciaroni M, Agnelli G, Caso V. et al. Causes and risk factors of cerebral ischemic events in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants for stroke prevention. Stroke 2019; 50 (08) 2168-2174
    CrossrefPubMedSuche in Google Scholar
  • 8 Carlisle MA, Shrader P, Fudim M. et al; ORBIT AF Patients and Investigators. Residual stroke risk despite oral anticoagulation in patients with atrial fibrillation. Heart Rhythm O2 2022; 3 (6Part A): 621-628
    PubMedSuche in Google Scholar
  • 9 Kaiser R, Dewender R, Mulkers M. et al. Procoagulant platelet activation promotes venous thrombosis. Blood 2024; 144 (24) 2546-2553
    PubMedSuche in Google Scholar
  • 10 Mackman N, Bergmeier W, Stouffer GA, Weitz JI. Therapeutic strategies for thrombosis: new targets and approaches. Nat Rev Drug Discov 2020; 19 (05) 333-352
    CrossrefPubMedSuche in Google Scholar
  • 11 Bánovčin Jr P, Škorňová I, Samoš M. et al. Platelet aggregation in direct oral factor Xa inhibitors-treated patients with atrial fibrillation: a pilot study. J Cardiovasc Pharmacol 2017; 70 (04) 263-266
    CrossrefPubMedSuche in Google Scholar
  • 12 Olivier CB, Weik P, Meyer M. et al. Dabigatran and rivaroxaban do not affect AA- and ADP-induced platelet aggregation in patients receiving concomitant platelet inhibitors. J Thromb Thrombolysis 2016; 42 (02) 161-166
    CrossrefPubMedSuche in Google Scholar
  • 13 Nehaj F, Sokol J, Mokan M, Ivankova J, Mokan M. Thrombin receptor agonist peptide-induced platelet aggregation is reduced in patients receiving dabigatran. Clin Appl Thromb Hemost 2018; 24 (02) 268-272
    PubMedSuche in Google Scholar
  • 14 Olivier CB, Weik P, Meyer M. et al. TRAP-induced platelet aggregation is enhanced in cardiovascular patients receiving dabigatran. Thromb Res 2016; 138: 63-68
    CrossrefPubMedSuche in Google Scholar
  • 15 Achilles A, Mohring A, Dannenberg L. et al. Dabigatran enhances platelet reactivity and platelet thrombin receptor expression in patients with atrial fibrillation. J Thromb Haemost 2017; 15 (03) 473-476
    PubMedSuche in Google Scholar
  • 16 Nehaj F, Sokol J, Ivankova J. et al. First evidence: TRAP-induced platelet aggregation is reduced in patients receiving xabans. Clin Appl Thromb Hemost 2018; 24 (06) 914-919
    CrossrefPubMedSuche in Google Scholar
  • 17 Steppich B, Dobler F, Brendel LC. et al. Effect of the FXa inhibitors rivaroxaban and apixaban on platelet activation in patients with atrial fibrillation. J Thromb Thrombolysis 2017; 43 (04) 490-497
    CrossrefPubMedSuche in Google Scholar
  • 18 Washington AV, Schubert RL, Quigley L. et al. A TREM family member, TLT-1, is found exclusively in the alpha-granules of megakaryocytes and platelets. Blood 2004; 104 (04) 1042-1047
    PubMedSuche in Google Scholar
  • 19 Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137 (02) 263-272
    CrossrefPubMedSuche in Google Scholar
  • 20 Hedley BD, Llewellyn-Smith N, Lang S. et al. Combined accurate platelet enumeration and reticulated platelet determination by flow cytometry. Cytometry B Clin Cytom 2015; 88 (05) 330-337
    PubMedSuche in Google Scholar
  • 21 Smith CW, Raslan Z, Parfitt L. et al. TREM-like transcript 1: a more sensitive marker of platelet activation than P-selectin in humans and mice. Blood Adv 2018; 2 (16) 2072-2078
    CrossrefPubMedSuche in Google Scholar
  • 22 Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci 2014; 69 (Suppl. 01) S4-S9
    PubMedSuche in Google Scholar
  • 23 Davizon-Castillo P, McMahon B, Aguila S. et al. TNF-α-driven inflammation and mitochondrial dysfunction define the platelet hyperreactivity of aging. Blood 2019; 134 (09) 727-740
    CrossrefPubMedSuche in Google Scholar
  • 24 Davizon-Castillo P, Rowley JW, Rondina MT. Megakaryocyte and platelet transcriptomics for discoveries in human health and disease. Arterioscler Thromb Vasc Biol 2020; 40 (06) 1432-1440
    PubMedSuche in Google Scholar
  • 25 Choudhury A, Chung I, Panja N, Patel J, Lip GYH. Soluble CD40 ligand, platelet surface CD40 ligand, and total platelet CD40 ligand in atrial fibrillation: relationship to soluble P-selectin, stroke risk factors, and risk factor intervention. Chest 2008; 134 (03) 574-581
    PubMedSuche in Google Scholar
  • 26 Choudhury A, Chung I, Blann AD, Lip GYH. Platelet surface CD62P and CD63, mean platelet volume, and soluble/platelet P-selectin as indexes of platelet function in atrial fibrillation: a comparison of “healthy control subjects” and “disease control subjects” in sinus rhythm. J Am Coll Cardiol 2007; 49 (19) 1957-1964
    CrossrefPubMedSuche in Google Scholar
  • 27 Nicolai L, Pekayvaz K, Massberg S. Platelets: orchestrators of immunity in host defense and beyond. Immunity 2024; 57 (05) 957-972
    CrossrefPubMedSuche in Google Scholar
  • 28 Larsen E, Palabrica T, Sajer S. et al. PADGEM-dependent adhesion of platelets to monocytes and neutrophils is mediated by a lineage-specific carbohydrate, LNF III (CD15). Cell 1990; 63 (03) 467-474
    CrossrefPubMedSuche in Google Scholar
  • 29 Cognasse F, Duchez AC, Audoux E. et al. Platelets as key factors in inflammation: focus on CD40L/CD40. Front Immunol 2022; 13: 825892
    CrossrefPubMedSuche in Google Scholar
  • 30 Coenen DM, Mastenbroek TG, Cosemans JMEM. Platelet interaction with activated endothelium: mechanistic insights from microfluidics. Blood 2017; 130 (26) 2819-2828
    CrossrefPubMedSuche in Google Scholar
  • 31 Dole VS, Bergmeier W, Patten IS, Hirahashi J, Mayadas TN, Wagner DD. PSGL-1 regulates platelet P-selectin-mediated endothelial activation and shedding of P-selectin from activated platelets. Thromb Haemost 2007; 98 (04) 806-812
    PubMedSuche in Google Scholar
  • 32 Pignatelli P, Pastori D, Bartimoccia S. et al. Anti Xa oral anticoagulants inhibit in vivo platelet activation by modulating glycoprotein VI shedding. Pharmacol Res 2016; 113 (Pt A): 484-489
    PubMedSuche in Google Scholar
  • 33 Huang J, Xiang Y, Zhang H. et al. Plasma level of interferon-γ predicts the prognosis in patients with new-onset atrial fibrillation. Heart Lung Circ 2020; 29 (07) e168-e176
    PubMedSuche in Google Scholar
  • 34 Fox KAA, Velentgas P, Camm AJ. et al; GARFIELD-AF Investigators. Outcomes associated with oral anticoagulants plus antiplatelets in patients with newly diagnosed atrial fibrillation. JAMA Netw Open 2020; 3 (02) e200107
    PubMedSuche in Google Scholar
  • 35 Kim JT, Lee JS, Kim BJ. et al. Effectiveness of adding antiplatelets to oral anticoagulants in patients with acute ischemic stroke with atrial fibrillation and concomitant large artery steno-occlusion. Transl Stroke Res 2020; 11 (06) 1322-1331
    PubMedSuche in Google Scholar
  • 36 Mazighi M, Köhrmann M, Lemmens R. et al; ACTIMIS Study Group. Safety and efficacy of platelet glycoprotein VI inhibition in acute ischaemic stroke (ACTIMIS): a randomised, double-blind, placebo-controlled, phase 1b/2a trial. Lancet Neurol 2024; 23 (02) 157-167
    PubMedSuche in Google Scholar
  • 37 Galli M, Gragnano F, Berteotti M. et al; Working Group of Thrombosis of the Italian Society of Cardiology. Antithrombotic therapy in high bleeding risk, part I: percutaneous cardiac interventions. JACC Cardiovasc Interv 2024; 17 (19) 2197-2215
    CrossrefPubMedSuche in Google Scholar